应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GILD 吉利德科学
盘前交易 04-23 05:12:04 EDT
66.95
+0.19
+0.28%
盘前
67.02
+0.07
+0.10%
04:30 EDT
最高
67.57
最低
66.74
成交量
562.23万
今开
66.93
昨收
66.76
日振幅
1.24%
总市值
834.85亿
流通市值
833.08亿
总股本
12.47亿
成交额
3.77亿
换手率
0.45%
流通股本
12.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美国研究综述-Blackstone、Ellington Financial、Netflix
Reuters · 04-19
美国研究综述-Blackstone、Ellington Financial、Netflix
瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。
智通财经 · 04-18
瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。
BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌
Reuters · 04-12
BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌
吉利德科学上涨1.25%,报68.97美元/股
金融界 · 04-12
吉利德科学上涨1.25%,报68.97美元/股
吉利德科学下跌1.23%,报70.02美元/股
金融界 · 04-05
吉利德科学下跌1.23%,报70.02美元/股
吉利德科学下跌1.22%,报71.21美元/股
金融界 · 04-04
吉利德科学下跌1.22%,报71.21美元/股
吉利德科学下跌1.21%,报72.0美元/股
金融界 · 04-03
吉利德科学下跌1.21%,报72.0美元/股
吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法
智通财经 · 03-29
吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法
【医疗健康周报】第12周:创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资;生物制药公司“CymaBay”以约43亿美元被吉利德并购
钛媒体APP · 03-27
【医疗健康周报】第12周:创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资;生物制药公司“CymaBay”以约43亿美元被吉利德并购
吉利德科学下跌1.22%,报73.08美元/股
金融界 · 03-22
吉利德科学下跌1.22%,报73.08美元/股
吉利德科学下跌1.23%,报73.3美元/股
金融界 · 03-16
吉利德科学下跌1.23%,报73.3美元/股
到 2026 年,吉利德 CAR-T 癌症疗法的产能将翻两番
Reuters · 03-15
到 2026 年,吉利德 CAR-T 癌症疗法的产能将翻两番
吉利德科学上涨1.23%,报76.0美元/股
金融界 · 03-14
吉利德科学上涨1.23%,报76.0美元/股
隔夜美股全复盘(3.8)| 三大股指集体收涨,英伟达涨逾4%,续创历史新高;诺和诺德大涨9%,口服减肥药Amycretin 3个月减重13%
格隆汇 · 03-08
隔夜美股全复盘(3.8)| 三大股指集体收涨,英伟达涨逾4%,续创历史新高;诺和诺德大涨9%,口服减肥药Amycretin 3个月减重13%
吉利德科学上涨1.21%,报73.51美元/股
金融界 · 03-08
吉利德科学上涨1.21%,报73.51美元/股
开发肿瘤靶向三特异性抗体!吉利德(GILD.US)与Merus达成超15亿美元合作
智通财经 · 03-07
开发肿瘤靶向三特异性抗体!吉利德(GILD.US)与Merus达成超15亿美元合作
BUZZ-Merus 因与吉利德合作发现基于抗体的疗法而上涨
Reuters · 03-06
BUZZ-Merus 因与吉利德合作发现基于抗体的疗法而上涨
吉利德科学上涨1.21%,报73.66美元/股
金融界 · 02-23
吉利德科学上涨1.21%,报73.66美元/股
嗡嗡声--美国股票走势-Wayfair Inc、Remitly Global、Monopar Therapeutics
Reuters · 02-22
嗡嗡声--美国股票走势-Wayfair Inc、Remitly Global、Monopar Therapeutics
嗡嗡声--美国股票走势-Nvidia Corp、皇家加勒比、Moderna
Reuters · 02-22
嗡嗡声--美国股票走势-Nvidia Corp、皇家加勒比、Moderna
加载更多
公司概况
公司名称:
吉利德科学
所属市场:
NASDAQ
上市日期:
--
主营业务:
吉利德科学公司于1987年6月22日在特拉华州成立,是一家以研究为基础的生物制药公司,致力于发现,开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病,炎性和纤维化疾病以及肿瘤学。
发行价格:
--
{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":66.95,"timestamp":1713816000000,"preClose":66.76,"halted":0,"volume":5622278,"hourTrading":{"tag":"盘前","latestPrice":67.02,"preClose":66.95,"latestTime":"04:30 EDT","volume":7,"amount":469.14,"timestamp":1713861000164},"delay":0,"floatShares":1244337698,"shares":1246969303,"eps":4.5,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.19,"latestTime":"04-23 05:12:04 EDT","open":66.93,"high":67.565,"low":66.74,"amount":377090908.17352,"amplitude":0.012358,"askPrice":67.54,"askSize":7,"bidPrice":66.8,"bidSize":7,"shortable":3,"etf":0,"ttmEps":4.5,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713879000000},"adr":0,"listingDate":696056400000,"adjPreClose":66.95,"adrRate":0,"dividendRate":0.04481,"preHourTrading":{"tag":"盘前","latestPrice":67.02,"preClose":66.95,"latestTime":"04:30 EDT","volume":7,"amount":469.14,"timestamp":1713861000164},"postHourTrading":{"tag":"盘后","latestPrice":66.95,"preClose":66.95,"latestTime":"19:57 EDT","volume":661321,"amount":44275336.2173,"timestamp":1713830247225},"volumeRatio":0.8013903028672427},"requestUrl":"/m/hq/s/GILD?invite=TIGER026","defaultTab":"news","newsList":[{"id":"2428668911","title":"美国研究综述-Blackstone、Ellington Financial、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2428668911","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428668911?lang=zh_cn&edition=full","pubTime":"2024-04-19 15:24","pubTimestamp":1713511479,"startTime":"0","endTime":"0","summary":" 路透社4月19日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价,其中包括黑石集团、艾灵顿金融公司和 Netflix。要闻 * 黑石集团 :Piper Sandler 将目标价从 146 美元下调至 143 美元 * Ellington Financial Inc :Jonestrading 给予其 \"持有 \"评级 * Netflix Inc :Pivotal Research将目标价从765美元上调至800美元 以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428567780","title":"瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428567780","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428567780?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:36","pubTimestamp":1713440183,"startTime":"0","endTime":"0","summary":"瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783006","title":"BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783006","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426783006?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:37","pubTimestamp":1712921821,"startTime":"0","endTime":"0","summary":" 4月12日 - ** Nurix Therapeutics Inc 的 股价在隔夜后续定价后盘前下跌 5.3%,报 16.30 美元。** 生物制药公司周四晚些时候宣布, ~1170万股,包括150万份预筹资认股权证,发行价为15美元,筹资总额为1.75亿美元。** Nurix本月早些时候宣布延长与吉利德科学公司 的合作。2023 年第四季度,该公司与辉瑞 达成新的合作。** Nurix 拥有约 4 920 万股已发行股票,市值约 8.46 亿美元** 截至本周四,公司股价已累计上涨 67** 摩根大通、Piper Sandler 和 Stifel 担任股票发行的账簿管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426296458","title":"吉利德科学上涨1.25%,报68.97美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426296458","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426296458?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:08","pubTimestamp":1712858894,"startTime":"0","endTime":"0","summary":"4月12日,吉利德科学(GILD)盘中上涨1.25%,截至02:08,报68.97美元/股,成交2.17亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将于(美东)盘后披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/12020840206400.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425341542","title":"吉利德科学下跌1.23%,报70.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425341542","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425341542?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:35","pubTimestamp":1712255745,"startTime":"0","endTime":"0","summary":"4月5日,吉利德科学(GILD)盘中下跌1.23%,截至02:35,报70.02美元/股,成交2.25亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/05023540127771.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424846875","title":"吉利德科学下跌1.22%,报71.21美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424846875","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424846875?lang=zh_cn&edition=full","pubTime":"2024-04-04 02:30","pubTimestamp":1712169021,"startTime":"0","endTime":"0","summary":"4月4日,吉利德科学(GILD)盘中下跌1.22%,截至02:30,报71.21美元/股,成交1.73亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/04023040122363.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424209790","title":"吉利德科学下跌1.21%,报72.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424209790","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424209790?lang=zh_cn&edition=full","pubTime":"2024-04-03 01:35","pubTimestamp":1712079326,"startTime":"0","endTime":"0","summary":"4月3日,吉利德科学(GILD)盘中下跌1.21%,截至01:35,报72.0美元/股,成交1.8亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/03013540103960.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2423171813","title":"吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2423171813","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2423171813?lang=zh_cn&edition=full","pubTime":"2024-03-29 07:50","pubTimestamp":1711669808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月29日,吉利德科学和Xilio Therapeutics宣布达成一项总额可能超过6亿美元的独家许可协议,两家公司将共同开发和商业化Xilio的肿瘤激活白介素12蛋白XTX301,该在研药物目前处于临床1期阶段。XTX301目前正在治疗晚期实体瘤患者的1期剂量递增试验中接受评估。在Xilio交付XTX301的指定临床数据后,吉利德可以选择获得XTX301的开发和商业化权利,并支付7500万美元的费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096048.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422529449","title":"【医疗健康周报】第12周:创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资;生物制药公司“CymaBay”以约43亿美元被吉利德并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2422529449","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2422529449?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:37","pubTimestamp":1711528648,"startTime":"0","endTime":"0","summary":"国内投融资方面,医药领域,创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资,核医学CRDMO“米度生物”融资近4亿元人民币。国外投融资方面,医药领域,生物制药公司“CymaBay”以约43亿美元被吉利德并购;生物技术领域,生物技术公司“Capstan Therapeutics”在B系列融资中筹集了1.75亿美元。医药“华诺泰生物”获得6亿人民币B轮融资日前,“华诺泰生物”正式宣布完成总额6亿元B轮融资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271642038b68fa12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271642038b68fa12&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421071560","title":"吉利德科学下跌1.22%,报73.08美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421071560","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421071560?lang=zh_cn&edition=full","pubTime":"2024-03-22 03:53","pubTimestamp":1711050837,"startTime":"0","endTime":"0","summary":"3月22日,吉利德科学(GILD)盘中下跌1.22%,截至03:53,报73.08美元/股,成交2.72亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/22035339946722.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419655901","title":"吉利德科学下跌1.23%,报73.3美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419655901","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419655901?lang=zh_cn&edition=full","pubTime":"2024-03-16 00:02","pubTimestamp":1710518562,"startTime":"0","endTime":"0","summary":"3月16日,吉利德科学(GILD)盘中下跌1.23%,截至00:02,报73.3美元/股,成交2.59亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/16000239875543.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419237919","title":"到 2026 年,吉利德 CAR-T 癌症疗法的产能将翻两番","url":"https://stock-news.laohu8.com/highlight/detail?id=2419237919","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419237919?lang=zh_cn&edition=full","pubTime":"2024-03-15 18:00","pubTimestamp":1710496855,"startTime":"0","endTime":"0","summary":"吉利德公司在 2017 年斥资近 120 亿美元收购了 Kite 公司,后者是 CAR-T 疗法这一新兴领域的领军企业之一,目前可治疗多种血癌。公司希望扩大 CAR-T 在美国的整体覆盖范围和市场份额。自2017年以来,六种获批的CAR-T产品已在美国施用了超过2.7万剂。最近,吉利德的 CAR-T 收入增长放缓,2023 年第四季度两种疗法的销售额连续下滑,约为 4.56 亿美元。该公司上个月表示,预计第一季度的CAR-T销售额将与上一季度持平或略有增长,但今年下半年的增长将有所回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419659245","title":"吉利德科学上涨1.23%,报76.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419659245","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419659245?lang=zh_cn&edition=full","pubTime":"2024-03-14 02:54","pubTimestamp":1710356075,"startTime":"0","endTime":"0","summary":"3月14日,吉利德科学(GILD)盘中上涨1.23%,截至02:54,报76.0美元/股,成交2.16亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/14025439842219.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417743147","title":"隔夜美股全复盘(3.8)| 三大股指集体收涨,英伟达涨逾4%,续创历史新高;诺和诺德大涨9%,口服减肥药Amycretin 3个月减重13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417743147","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2417743147?lang=zh_cn&edition=full","pubTime":"2024-03-08 05:21","pubTimestamp":1709846493,"startTime":"0","endTime":"0","summary":"三大股指集体收涨,英伟达涨逾4%,续创历史新高;诺和诺德大涨9%,口服减肥药Amycretin 3个月减重13%","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/703712","is_publish_highlight":false,"gpt_icon":0},{"id":"2417716283","title":"吉利德科学上涨1.21%,报73.51美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417716283","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417716283?lang=zh_cn&edition=full","pubTime":"2024-03-08 02:56","pubTimestamp":1709837792,"startTime":"0","endTime":"0","summary":"3月8日,吉利德科学(GILD)盘中上涨1.21%,截至02:56,报73.51美元/股,成交3.07亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:3月4日,吉利德科学获富国银行下调目标价至77美元,最新评级Equal Weight。4月25日,吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/08025639773438.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417766651","title":"开发肿瘤靶向三特异性抗体!吉利德(GILD.US)与Merus达成超15亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2417766651","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2417766651?lang=zh_cn&edition=full","pubTime":"2024-03-07 21:26","pubTimestamp":1709817992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月6日,吉利德宣布与Merus达成合作,双方将共同开发多款靶向新型肿瘤相关抗原的三特异性抗体。一旦行权,Merus将获得5600万美元的首付款以及2500万美元的股权投资,潜在交易金额超15亿美元。Merus官网公示的管线中均为双抗产品。2016年,Incyte与Merus就11个双特异性抗体达成合作。Incyte将支付1.2亿美元的预付款,并购买Merus8000万美元的普通股。此外,Merus还与礼来、先声药业、贝达药业等药企均有合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1083157.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417291502","title":"BUZZ-Merus 因与吉利德合作发现基于抗体的疗法而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2417291502","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417291502?lang=zh_cn&edition=full","pubTime":"2024-03-06 22:03","pubTimestamp":1709733794,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 3月6日 - ** 在美国上市的荷兰疗法开发商Merus NV 股价盘前上涨1.5%至50.70美元** 该公司称, (link),它将与吉利德科学公司 合作,研究和开发治疗癌症的抗体疗法。 ** Merus公司将领导两个项目的早期研究活动,吉利德公司将有权许可合作项目的开发** Merus公司将为初期目标获得5600万美元的预付现金,吉利德公司将投资2500万美元购买Merus公司的普通股。** 公司还有资格在潜在的开发和商业化里程碑上获得高达 15 亿美元的收益** 截至上次收盘,股价在过去12个月中上涨了一倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413117767","title":"吉利德科学上涨1.21%,报73.66美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2413117767","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2413117767?lang=zh_cn&edition=full","pubTime":"2024-02-23 22:50","pubTimestamp":1708699854,"startTime":"0","endTime":"0","summary":"2月23日,吉利德科学(GILD)盘中上涨1.21%,截至22:50,报73.66美元/股,成交2772.43万美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/02/23225039611130.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413624820","title":"嗡嗡声--美国股票走势-Wayfair Inc、Remitly Global、Monopar Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2413624820","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413624820?lang=zh_cn&edition=full","pubTime":"2024-02-22 23:55","pubTimestamp":1708617309,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月22日 - 在英伟达的出色业绩和预测刺激了今年人工智能引领的涨势之后,基准标普500指数周四短暂创下新纪录。美东时间10:31,道琼斯工业平均指数 上涨0.71%,报38888.1点。标准普尔500指数 上涨1.62%,报5062.63点;纳斯达克综合指数 上涨2.43%,报15959.39点。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413318297","title":"嗡嗡声--美国股票走势-Nvidia Corp、皇家加勒比、Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2413318297","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413318297?lang=zh_cn&edition=full","pubTime":"2024-02-22 20:13","pubTimestamp":1708604022,"startTime":"0","endTime":"0","summary":" * 个股走势的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月22日 - 英伟达业绩和预期大丰收,推动华尔街今年以来屡创新高的人工智能热潮再次升温,周四纳斯达克指数跳涨约2%。美东时间7:02,道指电子盘 上涨0.36%,报38815点。标准普尔500指数 上涨1.28%,报5,060.25点;纳斯达克100指数 上涨2.10%,报17,904.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.078},{"period":"3month","weight":-0.1576},{"period":"6month","weight":-0.1459},{"period":"1year","weight":-0.2266},{"period":"ytd","weight":-0.1736}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0412},{"period":"3month","weight":0.0306},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.2123},{"period":"ytd","weight":0.0514}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立,是一家以研究为基础的生物制药公司,致力于发现,开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病,炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.041198},{"month":2,"riseRate":0.393939,"avgChangeRate":0.002047},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.009403},{"month":4,"riseRate":0.545455,"avgChangeRate":0.01455},{"month":5,"riseRate":0.5625,"avgChangeRate":0.021083},{"month":6,"riseRate":0.625,"avgChangeRate":0.024943},{"month":7,"riseRate":0.53125,"avgChangeRate":0.013302},{"month":8,"riseRate":0.53125,"avgChangeRate":0.033833},{"month":9,"riseRate":0.5625,"avgChangeRate":0.031735},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00096},{"month":11,"riseRate":0.625,"avgChangeRate":0.039318},{"month":12,"riseRate":0.40625,"avgChangeRate":0.011587}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}